Healx

Healx is a biotechnology startup based in the UK, focused on repurposing drugs for rare diseases using its AI platform. Its AI platform, Healnet, uses natural language processing (NLP) to extract disease knowledge from published and proprietary data. Healx claims it can predict new treatments in three months and advance the drug to the clinical stage in 24 months. The company has also been working with various patient groups to collect data to be used for its AI software.

The company has 21 active projects, three of which are about to enter Phase I clinical trials. Its pipeline consists of drug candidates targeting rare neurological diseases, rare oncology diseases, and rare metabolic diseases. It also claims its mission is to progress 50 rare disease therapies to the clinic by 2025.

Key customers and partnerships

Healx has partnerships with the German pharmaceutical company Boehringer Ingelheim, the Children’s Tumor Foundation (CTF), and the Foundation for Angelman Syndrome Therapeutics. In August 2021 , it partnered with Ono Therapeutics to jointly identify new disease indications with high unmet needs.

Funding and financials

In October 2019, the company secured USD 56 million in Series B financing round led by Atomic. The funds were used to build a clinical-stage portfolio for rare diseases.